摘要
目的:观察聚乙二醇干扰素(pegylated interferon,PEG-IFN)治疗慢性丙型肝炎(chronic hepatitis C,CHC)与丙型肝炎病毒/乙型肝炎病毒(hepatitis C virus,HCV/hepatitis B virus,HBV)共感染者疗效观察.方法:临床选取CHC与HCV/HBV共感染患者各25例,抽取患者静脉血进行HCV RNA、HBV DNA以及肝脏纤维化指标.两组患者均采取PEG-IFN联合利巴韦林治疗48 wk,观察临床疗效.结果:经过1年治疗,CHC组患者血清中HCV RNA阴性检测率为52.0%,HCV/HBV组患者血清中HCV RNA阴性检测率为28.0%,两组比较差异具有显著性(P<0.05);2组患者治疗后血清血清谷丙转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(aspartate transaminase,A S T)均有不同程度的下降,与治疗前比较差异具有显著性(P<0.05);治疗后2组间血清ALT、AST比较差异无统计学意义(P>0.05);治疗后HCV组血清透明质酸(hyaluronic acid,HA)水平较治疗前明显降低(P<0.05).结论:PEG-IFN抗病毒治疗CHC的疗效要优于HCV/HBV共感染患者,但是PEG-IFN对HCV有一定的抑制作用,并部分改善机体免疫功能及肝功能.
AIM： To observe the clinical effect of pegylated interferon （PEG-IFN） in the treatment of chronic hepatitis C （CHC） and hepatitis C virus/hepatitis B virus （HCV/HBV） co-infection.
METHODS： Venous samples were collected from 25 CHC patients and 25 HCV/HBV patients for detection of HCV RNA, HBV DNA and liver fibrosis.
RESULTS： After one year of treatment, the rate of HCV RNA negativity was 52.0% in the CHC group and 28.0% in the HCV/HBV group （P 〈 0.05）; liver function was improved in both groups （both P 〈 0.05）, and the improvement did not differ significantly between the two groups （P 〉 0.05）; and posttreatment hyaluronic acid level was significantly lower than pretreatment value in the HCV group （P 〈 0.05）.
CONCLUSION： Although PEG-IFN has a better clinical effect in the treatment of CHC than HCV/HBV co-infection, it has an inhibitory effect on HCV and can partly improve the body’s immune function and liver function.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第30期3270-3274,共5页
World Chinese Journal of Digestology
